OBJECTIVESThis joint report from the Italian Society of Oral Pathology and Medicine (SIPMO) and Osteoporosis, Mineral Metabolism and Skeletal Diseases (SIOMMMS) aims to define the dental management of breast and prostate cancer patients under low-dose bone modifying agents (LD-BMAs), to reduce their risk to develop Medication-Related Osteonecrosis of the Jaw (MRONJ). The group believes that there is no clarity to date in the prevention/treatment of MRONJ within breast and prostate cancer patient groups, particularly regarding LD-BMA therapy to prevent Cancer Treatment Induced Bone Loss (CTIBL) and the different BMA therapies employed at different stages of the cancer treatment path. To the best of the knowledge of the authors, there are no joint reports, consensus papers or position papers on this specific topic in the literature.
MATERIALS AND METHODSAn interdisciplinary expert Italian panel, using the data available of the literature, developed these recommendations for optimal dental management for breast and prostate cancer patients undergoing LD-BMA therapy to prevent CTIBL.